| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.68 [0.59, 0.79] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.53 [0.22, 1.23] | | < 1 | | 77% | 2 studies (2/-) | 93.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.69 [0.44, 1.07] | | < 1 | | 46% | 2 studies (2/-) | 95.2 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.77 [0.62, 0.96] | | < 1 | | 66% | 3 studies (3/-) | 99.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 2.48 [1.43, 4.31] | | > 1 | | 56% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 1.63 [0.19, 14.17] | | > 1 | | 91% | 2 studies (2/-) | 67.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.31 [0.20, 0.48] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.42 [0.29, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.10 [0.03, 0.33] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.37 [0.22, 0.62] | | < 1 | | 53% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.29 [0.19, 0.45] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.29 [0.19, 0.46] | | < 1 | | 25% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.10 [0.07, 0.17] | | < 1 | | 57% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.47 [0.12, 1.80] | | < 1 | | 0% | 2 studies (2/-) | 86.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.48 [0.22, 1.08] | | < 1 | | 33% | 2 studies (2/-) | 96.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.52 [0.16, 1.64] | | < 1 | | 44% | 2 studies (2/-) | 86.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.58 [0.07, 5.02] | | < 1 | | 0% | 3 studies (3/-) | 68.7 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.14 [0.03, 0.53] | | < 1 | | 0% | 3 studies (3/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.96 [0.06, 15.39] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.13 [0.02, 0.72] | | < 1 | | 0% | 2 studies (2/-) | 99.0 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.03 [0.08, 13.41] | | < 1 | | 0% | 2 studies (2/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.40 [0.04, 4.62] | | < 1 | | 0% | 2 studies (2/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.43 [0.07, 2.61] | | < 1 | | 0% | 3 studies (3/-) | 82.1 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.49 [0.12, 2.01] | | < 1 | | 0% | 3 studies (3/-) | 83.7 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Eczema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.20 [0.08, 0.47] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.17] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.93 [0.03, 27.74] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.39 [0.14, 13.49] | | < 1 | | 0% | 1 study (1/-) | 38.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.42 [0.03, 5.48] | | < 1 | | 0% | 2 studies (2/-) | 74.4 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.81 [0.09, 6.95] | | < 1 | | 0% | 2 studies (2/-) | 57.6 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.46 [0.05, 3.98] | | < 1 | | 0% | 2 studies (2/-) | 75.7 % | some concern | not evaluable | moderate | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.46 [0.04, 6.06] | | < 1 | | 0% | 2 studies (2/-) | 71.9 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.05 [0.01, 0.21] | | < 1 | | 16% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.21 [0.02, 2.21] | | < 1 | | 0% | 2 studies (2/-) | 90.1 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 1.42 [0.11, 18.57] | | < 1 | | 0% | 2 studies (2/-) | 39.5 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.64 [0.12, 3.35] | | < 1 | | 0% | 2 studies (2/-) | 70.3 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.01, 0.06] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.39] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.16 [0.02, 1.32] | | < 1 | | 0% | 2 studies (2/-) | 95.5 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.64 [0.05, 8.39] | | < 1 | | 0% | 2 studies (2/-) | 63.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.83 [0.58, 13.89] | | < 1 | | 0% | 3 studies (3/-) | 10.0 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.65 [0.05, 8.46] | | < 1 | | 0% | 2 studies (2/-) | 62.9 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.08 [0.17, 6.66] | | < 1 | | 0% | 3 studies (3/-) | 46.9 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 6.60 [0.37, 116.99] | | < 1 | | 0% | 1 study (1/-) | 10.2 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 2.79 [0.14, 56.11] | | < 1 | | 0% | 1 study (1/-) | 25.4 % | NA | not evaluable | | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.23 [0.01, 5.17] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Urticaria TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.65 [0.05, 8.46] | | < 1 | | 0% | 2 studies (2/-) | 62.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.38 [0.13, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.4 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.84 [0.35, 2.02] | | < 1 | | 0% | 1 study (1/-) | 64.9 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 2.36 [0.45, 12.26] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.17 [0.31, 4.40] | | < 1 | | 0% | 1 study (1/-) | 40.8 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.93 [0.19, 4.66] | | < 1 | | 0% | 1 study (1/-) | 53.3 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.93 [0.06, 15.00] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.32 [0.58, 3.03] | | < 1 | | 0% | 1 study (1/-) | 25.4 % | NA | not evaluable | | non important | - |
| Erythema AE (grade 3-4) | 0.47 [0.02, 13.95] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.45 [0.20, 1.02] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.01 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 3.75 [0.17, 83.63] | | < 1 | | 0% | 1 study (1/-) | 20.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.93 [0.06, 15.00] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Lacrimation increased AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.02 [0.00, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 0.18 [0.02, 1.58] | | < 1 | | 0% | 1 study (1/-) | 93.7 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 2.36 [0.45, 12.26] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Oropharyngeal pain AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
